Mean cocaine consumed (mg/kg) over 10 days. by Christopher Rowan (21499924)

Mean T2* and T2 relaxation time of the 10 participants. by Charlotte Zaeske (12101949)

Summary of predictors that increase (+ UC) and decrease (- UC) the dose of propofol for the three statistical models used for data analysis. by Chiara E. Hampton (16484687)

Subjects:

Effects of <i>trans ε</i>-viniferin at 10 mg/kg on amyloid load. by Martial Caillaud (6383672)

Baseline patient characteristics. by Oscar F. C. van den Bosch (22184246)

MgOx treatment is not sufficient to alter S10 reporter activity. by Justin Greene (306625)

Methyl Gallate (MG) treatment decreases hepatocellular carcinoma (HCC) cell survival. by Chien-Yu Huang (802982)

Effects of <i>trans ε</i>-viniferin at 10 mg/kg on amyloid deposits and neuroinflammation in cortex. by Martial Caillaud (6383672)

Effects of <i>trans ε</i>-viniferin at 10 mg/kg on amyloid deposits and neuroinflammation in hippocampus. by Martial Caillaud (6383672)

MVK activates microglia and decreases phagocytosis. by Ren Y. Sato (16914027)

Hypothesis that explains and predicts expansion of ages of KD due to decreased IgG levels. by Hiromi Yamaguchi (2396248)

Pre-treatment of OJS did not mitigate DRG activation but decreased inflammatory responses in BMDM. by Patrice Cunningham (12914917)

Decreased clonogenic capacity of U87MG and U251MG glioma cells dependent on SHG-44 concentration. by Denis Mustafov (19137870)

Mast cell density and tactile sensitivity decreased after 10 preventative imatinib treatments followed by repeated MI challenges. by Jaclyn M. Kline (9565161)

“…(B) Tactile sensitivity in sensitized mice preventatively treated with imatinib or NT and then 10 daily MI challenges. Results reported as mean ± SEM of the percent decrease from baseline in the withdrawal threshold for each treatment group, n = 18/treatment group. …”

Data_Sheet_1_Regulatory B Cells Are Decreased and Functionally Impaired in Myasthenia Gravis Patients.docx by Ye Lin (613248)

Trial profile. by Chanel Avenant (409756)

“…Both contraceptives substantially decreased, from D0 to 25W, the total testosterone [DMPA-IM D0 0.560, 25W 0.423 nmol/L, -24.3% (p < 0.0001); NET-EN D0 0.551, 25W 0.253 nmol/L, -54.1%, (p < 0.0001)], SHBG [DMPA-IM D0 45.0, 25W 32.7 nmol/L, -29.8% (p < 0.0001); NET-EN D0 50.2, 25W 17.6 nmol/L, -65.1% (p < 0.0001)], and calculated free testosterone levels [DMPA-IM D0 6.87, 25W 5.38 pmol/L, -17.2% (p = 0.0371); NET-EN D0 6.00, 25W 3.70, -40.0% (p < 0.0001)]. …”

Rhinorrhea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Vomit-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Symptoms free-days up to day 10. by Bruno Martins Tomazini (6509528)

“…The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Diarrhea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”